Non-small cell lung cancer
Conditions
Interventions
Single group:Card Rayleigh bead sheet resistance + cisplatin or carboplatin double medicine
Sponsors
Xuzhou City Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. The pathological histology and cytology diagnosed stage III resectable non-small cell lung cancer; 3. According to RECIST 1.1 standard, participants must have a measurable target lesions by CT or MRI. 4. Patients into the group of the world health organization (WHO)/eastern group (ECOG) tumor physical status score (PS) to 0 or 1; 5. The life expectancy for 3 months or more; 6. Patients signed the informed consent and voluntary to join this study; 7. No serious damage of liver and kidney function, the function of the organ level must meet the following requirements: the ANC acuity 1.5 x 10^9/L; PLT acuity 90x10^9/L; Hb 90 g/L or higher; 1 ULN TBIL or less; ALT and AST acuities were 1.5 ULN, ALP 2.5 ULN or less; With liver metastases, ALT and AST 5 ULN or less; BUN and Cr 1 ULN and creatinine clearance or greater or less 50 mL/min (Cockcroft - Gault formula); LVEF 50% or higher; Fridericia method of correction of QT interphase < 450 ms (QTcF) men and women < 470 ms; INR 1.5 ULN, or less ACTT acuities were 1.5 ULN
Exclusion criteria
Exclusion criteria: 1. Always received for any of the lung cancer treatment, including chemotherapy or radiation therapy; 2. Drive gene positive patients, known to carry EGFR mutation or ALK, ROS1 gene translocation; 3. Allergic to any drugs or gao min physique patients, patients with autoimmune disease; 4. There can't be controlled by drainage or other methods of third space effusion (such as a large number of pleural fluid and ascites); 5. The use of steroids for over 50 days, or need long-term use of steroids; 6. Uncontrolled symptomatic brain metastases or mental abnormalities can not correctly describe the subjective symptoms; 7. At the same time to accept any other anti-tumor treatment, including antitumor proprietary Chinese medicine and immune preparation; 8. Unable to swallow, chronic diarrhea and intestinal obstruction, there are a variety of factors influencing drug taking and absorption; 9. In the group of five years before other malignant tumor, had to effect a radical cure for the purpose of treatment of cervical carcinoma in situ or skin except skin squamous or basal cell carcinoma; 10. Pregnancy and lactation women have fertility, but refused to take contraceptive measures; 11. A history of severe heart disease or, including: recorded history of congestive heart failure, high-risk sexual arrhythmia, beyond the control of the drug treatment of angina pectoris, clinical definite heart valve disease, severe myocardial infarction history of plug and resistant hypertension; 12. Has received allogeneic tissue/solid organ transplant; 13. According to the researcher's judgment, there is serious to endanger the safety of patients, the patients completed studies or associated with disease (in the absence of clinical control of high blood pressure, diabetes, thyroid disease, etc.); 14. The researchers determine other doesn't fit into the situation of the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MPR; | — |
Countries
China
Contacts
Public ContactYin Hai-Tao
Xuzhou City Central Hospital
Outcome results
None listed